# VJET earnings call intelligence

LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/VJET) · [Earnings tab](https://www.lopjlb.com/stock/VJET?tab=earnings)

Updated: 2026-11-16T02:37:14

Quarters analyzed: 1

## Cross-quarter narrative

As of the 2022 Q1 call, Ra Medical (VJET) reported steady enrollment in its pivotal atherectomy trial, with 107 of 125 patients enrolled and a target to complete enrollment in Q3 2022, though COVID-19 introduced timing uncertainty. The company advanced multiple product initiatives: DABRA 2.0 and RX catheters, laser system upgrades (all 510(k) submissions on track), and early-stage intravascular lithotripsy (IVL) development. Commercial shipments remained paused, with revenue limited to clinical study supply; the addressable U.S. market for CTO and atherectomy was estimated at $900 million. Financially, the company raised $9.7 million in equity, bringing cash to $17.7 million against a quarterly operating cash burn of approximately $8.6 million. SG&A decreased year-over-year while R&D increased for engineering and clinical work. A strategic alternatives review was underway, potentially requiring additional capital. Leadership transition risk emerged with the CFO's resignation and an interim search underway. Supply chain disruptions were cited as affecting engineering project schedules, and macroeconomic headwinds were noted as a broader concern. Overall, the call reflected a clinical-stage company progressing its pipeline while navigating funding, enrollment, and operational uncertainties. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 words. 180 word

## Latest CallCard · Q1

Ra Medical reports steady enrollment in pivotal atherectomy trial (107/125), targets Q3 enrollment completion; advancing DABRA 2.0 and RX catheters, laser upgrades, and early IVL development; CFO departing; strategic alternatives review underway. Cash $17.7M after $9.7M raise.

**Guidance:** vague — No formal financial guidance; clinical enrollment target end of Q3 2022 but uncertain; DABRA 2.0 510(k) clearance expected Q3 2022; DABRA RX 510(k) filing end of 2022; laser upgrades 510(k) Q3 2022; IVL preclinical studies next few months.

**Tone:** mgmt 0.2 · Q&A pressure 0.3 · divergence 0.2

Management highlights steady clinical enrollment progress, multiple product development milestones on track, but acknowledges COVID, supply chain, macro uncertainties and announces strategic alternatives review.

### Demand visibility

Limited near-term demand visibility; commercial shipments paused, only supplying clinical study; addressable market estimated at $900M US for CTO+atherectomy.

Revenue minimal ($9K Q1) from clinical study product use; commercial shipments paused since late 2020; atherectomy clearance needed to expand market beyond CTO; third-party estimates combined US market ~$900M.

### Margins / costs

Gross loss on minimal revenue; operating cash burn ~$8.6M/Q1; SG&A reduced YoY; R&D increased for engineering and clinical study.

Q1 revenue $9K, gross loss $86K; SG&A $2.3M vs $3.7M prior year (legal, personnel, stock comp lower); R&D $3.1M vs $2.8M (engineering and clinical study); cash used in operations $8.6M; cash balance $17.7M after $9.7M offering.

### Capital allocation

Funded operations with $9.7M equity raise; cash $17.7M; reviewing strategic alternatives that may require additional capital.

Completed public offering Feb 2022 net proceeds $9.7M; cash used in operations $8.6M in Q1; cash and equivalents $17.7M at quarter end; management and Board reviewing strategic alternatives with investment bank that could require additional capital.

### Milestones

- **Pivotal atherectomy clinical trial enrollment** [on_track]: 107/125 subjects enrolled as of May 16; 8 sites active; target full enrollment end of Q3 2022 but COVID impact unpredictable.
- **DABRA 2.0 catheter 510(k) clearance** [on_track]: 510(k) submitted Feb 2022; expect clearance Q3 2022.
- **DABRA RX catheter development** [on_track]: Design selected after Dec 2021 preclinical; finalizing engineering later 2022; targeting 510(k) filing end of 2022.
- **Laser system upgrades 510(k)** [on_track]: Includes new CPU and reliability improvements; on track for Q3 2022 submission.
- **Intravascular lithotripsy (IVL) development** [new]: Prototype systems fabricated; preclinical studies planned next few months; design concept work and development project initiation targeted H2 2022.
- **CFO resignation and interim search** [at_risk]: Andrew Jackson resigned, leaving later this quarter; interim CFO candidates under discussion.
- **Strategic alternatives review** [new]: Review with investment bank underway; could result in strategy changes; no timing commitment.

### Fears / risks

- **Clinical trial enrollment delay**: COVID-19 impact makes enrollment completion date unpredictable
- **Supply chain disruptions**: Persistent supply chain issues affect engineering project schedules
- **Macroeconomic headwinds**

## Quarter one-liners

- **2022 Q1:** Ra Medical reports steady enrollment in pivotal atherectomy trial (107/125), targets Q3 enrollment completion; advancing DABRA 2.0 and RX catheters, laser upgrades, and early IVL development; CFO departing; strategic alternatives review underway. Cash $17.7M after $9.7M raise.

## Guidance path

2022 Q1:vague

---

Research context only. Not personalized investment advice.

API: `GET /bff/api/bigfive/earnings-intel/VJET`
